Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail) (Sales [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Servier [Member]
Concentration Risk [Line Items]
Percentage of all significant revenue earned	51.60%	17.30%
Boehringer [Member]
Concentration Risk [Line Items]
Percentage of all significant revenue earned	24.80%	18.40%	15.60%
Gilead [Member]
Concentration Risk [Line Items]
Percentage of all significant revenue earned	13.80%
Pfizer [Member]
Concentration Risk [Line Items]
Percentage of all significant revenue earned	6.00%	8.70%	10.80%
Government Agencies [Member]
Concentration Risk [Line Items]
Percentage of all significant revenue earned	2.20%	6.50%	17.70%
Eli Lilly [Member]
Concentration Risk [Line Items]
Percentage of all significant revenue earned	1.40%	48.90%	54.00%